Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models
| Autor: | John J. Tentler, Natalie J. Serkova, John J. Arcaroli, Amy M. Brown, Aik Choon Tan, Fortunato Ciardiello, M. Pia Morelli, Sujatha Nallapareddy, Erica L. Bradshaw-Pierce, Todd M. Pitts, Manuel Hidalgo, Gillian N. Kulikowski, S. Gail Eckhardt |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Cancer Research
Mice Nude Apoptosis Biology Hydroxamic Acids Ligands medicine.disease_cause Article Proto-Oncogene Proteins p21(ras) Mice Cell Movement In vivo Cell Line Tumor Proto-Oncogene Proteins Antineoplastic Combined Chemotherapy Protocols medicine Animals Cluster Analysis Humans Nuclear Magnetic Resonance Biomolecular Vorinostat Cell Proliferation Cell growth Gene Expression Profiling MEK inhibitor Cell Cycle Cell cycle Xenograft Model Antitumor Assays Histone Deacetylase Inhibitors Oncology Positron-Emission Tomography Mutation ras Proteins Selumetinib Cancer research Benzimidazoles Female Histone deacetylase KRAS Colorectal Neoplasms Signal Transduction medicine.drug |
| Zdroj: | Clinical Cancer Research. 18:1051-1062 |
| ISSN: | 1557-3265 1078-0432 |
| Popis: | Purpose: Despite the availability of several active combination regimens for advanced colorectal cancer (CRC), the 5-year survival rate remains poor at less than 10%, supporting the development of novel therapeutic approaches. In this study, we focused on the preclinical assessment of a rationally based combination against KRAS-mutated CRC by testing the combination of the MEK inhibitor, selumetinib, and vorinostat, a histone deacetylase (HDAC) inhibitor. Experimental Design: Transcriptional profiling and gene set enrichment analysis (baseline and posttreatment) of CRC cell lines provided the rationale for the combination. The activity of selumetinib and vorinostat against the KRAS-mutant SW620 and SW480 CRC cell lines was studied in vitro and in vivo. The effects of this combination on tumor phenotype were assessed using monolayer and 3-dimensional cultures, flow cytometry, apoptosis, and cell migration. In vivo, tumor growth inhibition, 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET), and proton nuclear magnetic resonance were carried out to evaluate the growth inhibitory and metabolic responses, respectively, in CRC xenografts. Results: In vitro, treatment with selumetinib and vorinostat resulted in a synergistic inhibition of proliferation and spheroid formation in both CRC cell lines. This inhibition was associated with an increase in apoptosis, cell-cycle arrest in G1, and reduced cellular migration and VEGF-A secretion. In vivo, the combination resulted in additive tumor growth inhibition. The metabolic response to selumetinib and vorinostat consisted of significant inhibition of membrane phospholipids; no significant changes in glucose uptake or metabolism were observed in any of the treatment groups. Conclusion: These data indicate that the rationally based combination of the mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor, selumetinib, with the HDAC inhibitor vorinostat results in synergistic antiproliferative activity against KRAS-mutant CRC cell lines in vitro. In vivo, the combination showed additive effects that were associated with metabolic changes in phospholipid turnover, but not on FDG-PET, indicating that the former is a more sensitive endpoint of the combination effects. Clin Cancer Res; 18(4); 1051–62. ©2011 AACR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|